288 related articles for article (PubMed ID: 24832624)
1. Endogenous neurotoxic dopamine derivative covalently binds to Parkinson's disease-associated ubiquitin C-terminal hydrolase L1 and alters its structure and function.
Contu VR; Kotake Y; Toyama T; Okuda K; Miyara M; Sakamoto S; Samizo S; Sanoh S; Kumagai Y; Ohta S
J Neurochem; 2014 Sep; 130(6):826-38. PubMed ID: 24832624
[TBL] [Abstract][Full Text] [Related]
2. Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism.
Kawai H; Makino Y; Hirobe M; Ohta S
J Neurochem; 1998 Feb; 70(2):745-51. PubMed ID: 9453570
[TBL] [Abstract][Full Text] [Related]
3. Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system.
Xilouri M; Kyratzi E; Pitychoutis PM; Papadopoulou-Daifoti Z; Perier C; Vila M; Maniati M; Ulusoy A; Kirik D; Park DS; Wada K; Stefanis L
Hum Mol Genet; 2012 Feb; 21(4):874-89. PubMed ID: 22076440
[TBL] [Abstract][Full Text] [Related]
4. Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1.
Kabuta T; Setsuie R; Mitsui T; Kinugawa A; Sakurai M; Aoki S; Uchida K; Wada K
Hum Mol Genet; 2008 May; 17(10):1482-96. PubMed ID: 18250096
[TBL] [Abstract][Full Text] [Related]
5. Dopamine transporter and catechol-O-methyltransferase activities are required for the toxicity of 1-(3',4'-dihydroxybenzyl)-1,2,3, 4-tetrahydroisoquinoline.
Kawai H; Kotake Y; Ohta S
Chem Res Toxicol; 2000 Dec; 13(12):1294-301. PubMed ID: 11123971
[TBL] [Abstract][Full Text] [Related]
6. S-Mercuration of ubiquitin carboxyl-terminal hydrolase L1 through Cys152 by methylmercury causes inhibition of its catalytic activity and reduction of monoubiquitin levels in SH-SY5Y cells.
Toyama T; Abiko Y; Katayama Y; Kaji T; Kumagai Y
J Toxicol Sci; 2015 Dec; 40(6):887-93. PubMed ID: 26558469
[TBL] [Abstract][Full Text] [Related]
7. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.
Yasuda T; Nihira T; Ren YR; Cao XQ; Wada K; Setsuie R; Kabuta T; Wada K; Hattori N; Mizuno Y; Mochizuki H
J Neurochem; 2009 Feb; 108(4):932-44. PubMed ID: 19141079
[TBL] [Abstract][Full Text] [Related]
8. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases.
Choi J; Levey AI; Weintraub ST; Rees HD; Gearing M; Chin LS; Li L
J Biol Chem; 2004 Mar; 279(13):13256-64. PubMed ID: 14722078
[TBL] [Abstract][Full Text] [Related]
9. Glutathione-mediated reversibility of covalent modification of ubiquitin carboxyl-terminal hydrolase L1 by 1,2-naphthoquinone through Cys152, but not Lys4.
Toyama T; Shinkai Y; Yazawa A; Kakehashi H; Kaji T; Kumagai Y
Chem Biol Interact; 2014 May; 214():41-8. PubMed ID: 24582816
[TBL] [Abstract][Full Text] [Related]
10. Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1.
Koharudin LM; Liu H; Di Maio R; Kodali RB; Graham SH; Gronenborn AM
Proc Natl Acad Sci U S A; 2010 Apr; 107(15):6835-40. PubMed ID: 20231490
[TBL] [Abstract][Full Text] [Related]
11. N-terminal truncated UCH-L1 prevents Parkinson's disease associated damage.
Kim HJ; Kim HJ; Jeong JE; Baek JY; Jeong J; Kim S; Kim YM; Kim Y; Nam JH; Huh SH; Seo J; Jin BK; Lee KJ
PLoS One; 2014; 9(6):e99654. PubMed ID: 24959670
[TBL] [Abstract][Full Text] [Related]
12. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants.
Nishikawa K; Li H; Kawamura R; Osaka H; Wang YL; Hara Y; Hirokawa T; Manago Y; Amano T; Noda M; Aoki S; Wada K
Biochem Biophys Res Commun; 2003 Apr; 304(1):176-83. PubMed ID: 12705903
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1.
Konya C; Hatanaka Y; Fujiwara Y; Uchida K; Nagai Y; Wada K; Kabuta T
Neurochem Int; 2011 Aug; 59(2):251-8. PubMed ID: 21693148
[TBL] [Abstract][Full Text] [Related]
14. Insights into links between familial and sporadic Parkinson's disease: physical relationship between UCH-L1 variants and chaperone-mediated autophagy.
Kabuta T; Wada K
Autophagy; 2008 Aug; 4(6):827-9. PubMed ID: 18635949
[TBL] [Abstract][Full Text] [Related]
15. Cloning and expression analysis of a Parkinson's disease gene, uch-L1, and its promoter in zebrafish.
Son OL; Kim HT; Ji MH; Yoo KW; Rhee M; Kim CH
Biochem Biophys Res Commun; 2003 Dec; 312(3):601-7. PubMed ID: 14680807
[TBL] [Abstract][Full Text] [Related]
16. Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.
Lee YC; Hsu SD
Curr Protein Pept Sci; 2017; 18(7):733-745. PubMed ID: 26899237
[TBL] [Abstract][Full Text] [Related]
17. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
18. DJ-1 and UCH-L1 gene activity patterns in the brains of controls, Parkinson and schizophrenia patients and in rodents.
Galter D; Westerlund M; Belin AC; Olson L
Physiol Behav; 2007 Sep; 92(1-2):46-53. PubMed ID: 17599367
[TBL] [Abstract][Full Text] [Related]
19. The functions of UCH-L1 and its relation to neurodegenerative diseases.
Setsuie R; Wada K
Neurochem Int; 2007; 51(2-4):105-11. PubMed ID: 17586089
[TBL] [Abstract][Full Text] [Related]
20. Substrate recognition and catalysis by UCH-L1.
Luchansky SJ; Lansbury PT; Stein RL
Biochemistry; 2006 Dec; 45(49):14717-25. PubMed ID: 17144664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
